Taro Pharmaceutical Industries Ltd. (TARO) Investment Research Dashboard
About Taro Pharmaceutical Industries Ltd. (TARO) stock analysis
Get live TARO stock price $42.98, comprehensive Taro Pharmaceutical Industries Ltd. stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time TARO stock data and investment insights.
Loading chart data...
Taro Pharmaceutical Industries Ltd. (TARO) Overview
Taro Pharmaceutical Industries Ltd. (TARO) is a publicly traded company in the Healthcare sector , specifically within the Drug Manufacturers - Specialty & Generic industry . As of the latest trading session, TARO trades at $42.98 with a market capitalization of 1.62B . Over the past 52 weeks, TARO has traded between $32.67 and $45.76 , with the current price positioned at approximately 79% of ...
Key Takeaways
- Operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic)
- Market cap: 1.62B
- Current price: $42.98
- 52-week range: $32.67 - $45.76
- P/E ratio: 30.05
Investment Score
A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.
Score unavailable for this asset.
0-39
Defensive posture
40-54
Mixed / wait for confirmation
55-69
Constructive setup
70-100
Attractive zone
Total Score
Value
Cheapness vs fundamentals and cash generation
Quality
Durability of profitability and balance sheet
Momentum
Price trend strength and persistence
Company Overview
Taro Pharmaceutical Industries Ltd. operates as a scientifically-driven pharmaceutical enterprise, specializing in the development, manufacturing, and commercialization of both prescription and over-the-counter medications. Its market reach spans the...
Company Information
- CEO
- Uday V. Baldota
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 1554
Contact Information
- Website
- https://www.taro.com
- Address
- 14 Hakitor Street
- Country
- IL
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Growth-oriented company with premium valuation (P/E: 30.1)
✓ Lower volatility stock (Beta: 0.56) may provide portfolio stability
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Taro Pharmaceutical Industries Ltd. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Taro Pharmaceutical Industries Ltd.
- ⚠Investors should consider how Taro Pharmaceutical Industries Ltd. fits within their overall portfolio allocation
- ⚠Premium valuation (P/E: 30.1) requires strong growth to justify
Market Cap
1.62B
P/E Ratio (TTM)
30.05
Beta
0.56
Data Sources & Methodology
Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.
Related Stocks
Compare TARO with peer companies:
- Price
- $28.00+0.00% (1D)
- Market cap
- 1.77B
- Price
- $37.97-0.58% (1D)
- Market cap
- 1.88B
- Price
- $14.75+0.00% (1D)
- Market cap
- 1.87B
- Price
- $25.59+0.00% (1D)
- Market cap
- 2.21B
- Price
- $3.59+4.51% (1D)
- Market cap
- 212.99M
- Price
- $21.55+0.00% (1D)
- Market cap
- 1.83B
- Price
- $23.94+0.00% (1D)
- Market cap
- 1.61B
- Price
- $30.98+0.00% (1D)
- Market cap
- 919.17M
- Price
- $12.50+0.00% (1D)
- Market cap
- 1.33B
- Price
- $3.88-0.89% (1D)
- Market cap
- 65.15M
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.
Healthcare (1D)
78/100 ⭐⭐⭐⭐⭐
- Overall
- +0.7%
- NYSE
- +0.6%
- NASDAQ
- +0.7%
| Sector | 1D | 1W | 1M | P/E | Score |
|---|---|---|---|---|---|
| Financial Services | +2.2% | +3.1% | +4.3% | 19.3 | 98/100⭐⭐⭐⭐⭐ |
| Healthcare | +0.7% | +1.3% | +1.6% | 24.1 | 78/100⭐⭐⭐⭐⭐ |
| Communication Services | +1.4% | -0.7% | +2.9% | 22.2 | 74/100⭐⭐⭐⭐⭐ |
| Consumer Defensive | -0.2% | +1.8% | +0.7% | 29.7 | 64/100⭐⭐⭐⭐ |
| Basic Materials | +0.4% | +1.2% | -0.2% | 25.2 | 61/100⭐⭐⭐⭐ |
| Real Estate | -0.5% | +0.0% | -2.5% | 29.2 | 43/100⭐⭐⭐ |
| Energy | -2.1% | -3.7% | -4.1% | 19.1 | 39/100⭐⭐ |
| Utilities | -1.0% | +0.0% | -4.4% | 26.8 | 37/100⭐⭐ |
| Industrials | +0.6% | +0.4% | -9.9% | 30.1 | 23/100⭐ |
| Consumer Cyclical | +0.5% | -1.5% | -5.8% | 43.0 | 18/100⭐ |
| Technology | +0.6% | -1.6% | -7.2% | 40.7 | 15/100⭐ |
Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-28.